Rare diseases are not rare: Challenges and opportunities for OM research
探讨运营管理研究如何帮助改善罕见病患者的治疗可及性，从政府、行业、保险公司和患者角度分析挑战与机遇，并指出未来研究方向。
There are more than 7,000 known rare diseases, yet around <mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" overflow="scroll"> <mml:mn>95</mml:mn> <mml:mi mathvariant="normal">%</mml:mi> </mml:math> of them lack effective treatments. This paper explores how Operations Management (OM) research can help improve patient access to rare disease treatments. We first examine key challenges and opportunities from the perspectives of governments, industry, insurers, and patients. We then outline future research directions, focusing on regulatory frameworks, subsidy and incentive schemes, pricing and coverage decisions, (bio)pharmaceutical manufacturing, and challenges in developing economies. The application of OM methodologies to the rare disease landscape is still limited, but offers significant potential to advance new drug development, increase patient access to correct diagnosis and treatment, and reduce healthcare inequalities for patients with rare diseases.